ARL6IP6

Across TCGA pan-cancer cohorts, ARL6IP6 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ARL6IP6’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where ARL6IP6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARL6IP6 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, PDAC, and LSCC are the cancer types where ARL6IP6 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL6IP6 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	II,III,IV	−0.324	<.001	8	view →
PDAC	Male	II,III,IV	+0.329	.027	4	view →
LSCC	All	II,III,IV	−0.194	<.001	4	view →
OV	All	All	−0.615	.005	2	view →
CCRCC	All	All	+0.138	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ARL6IP6–LUAD

Open the LUAD breakdown →